Trials / Recruiting
RecruitingNCT04634552
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 510 (estimated)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Talquetamab | Talquetamab will be administered SC until disease progression. |
Timeline
- Start date
- 2021-02-01
- Primary completion
- 2026-03-31
- Completion
- 2029-03-30
- First posted
- 2020-11-18
- Last updated
- 2026-04-13
Locations
78 sites across 11 countries: United States, Belgium, China, France, Germany, Israel, Japan, Netherlands, Poland, South Korea, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04634552. Inclusion in this directory is not an endorsement.